Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.77 |
| ▸ | KMO | O15229 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.63 |
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | MITF | O75030 | 1/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | GFER | P55789 | 1/20 | 0.63 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.63 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.60 |
| ▸ | TNKS | O95271 | 1/20 | 0.60 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.60 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.60 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.60 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.60 |
| ▸ | NPC1 | O15118 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30266789 | 0.91 | AKR1C3 (0.92) | AKR1C3KMOALDH1A1KDM4EPARP10 | |
| SCHEMBL1042631 | 0.91 | AKR1C3 (0.92) | AKR1C3KMOALDH1A1KDM4EPARP10 | |
| SCHEMBL6866104 | 0.90 | MEN1 (0.69) | AKR1C3KMOALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL28701196 | 0.89 | AKR1C3 (0.96) | AKR1C3KMOKDM4EPARP10TNKS | |
| SCHEMBL29546656 | 0.89 | AKR1C3 (0.96) | AKR1C3KMOKDM4EPARP10TNKS | |
| SCHEMBL4320685 | 0.89 | AKR1C3 (0.96) | AKR1C3KMOKDM4EPARP10TNKS | |
| SCHEMBL29436294 | 0.88 | ALDH1A1 (0.66) | AKR1C3KMOALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL8903435 | 0.88 | ALDH1A1 (0.66) | AKR1C3KMOALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL310329 | 0.88 | ALDH1A1 (0.66) | AKR1C3KMOALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL6380428 | 0.88 | AKR1C3 (0.73) | AKR1C3KMOKMT2AKDM4EPARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109734908-B | Polyamide acid and preparation method thereof, polyimide and preparation method of polyimide film | 武汉柔显科技股份有限公司 | 2021-01-12 | — | — | CN | claimed |
| US-8575335-B2 | Method of preparing nitrogen-doped graphene and nitrogen-doped graphene prepared thereby | UNIST ACADEMY-INDUSTRY RESEARCH CORPORATION (KR) | 2013-11-05 | — | — | US | claimed |
| US-20120149897-A1 | METHOD OF PREPARING NITROGEN-DOPED GRAPHENE AND NITROGEN-DOPED GRAPHENE PREPARED THEREBY | UNIST (ULSAN NATIONAL INSTITUTE OF SCIENCE AND TECHNOLOGY) (KR) | 2012-06-14 | — | — | US | claimed |
| CN-109734908-B | Polyamide acid and preparation method thereof, polyimide and preparation method of polyimide film | 武汉柔显科技股份有限公司 | 2021-01-12 | — | — | CN | disclosed |
| CN-109734908-B | Polyamide acid and preparation method thereof, polyimide and preparation method of polyimide film | 武汉柔显科技股份有限公司 | 2021-01-12 | — | — | CN | disclosed |
| US-20140329866-A1 | OMEGA-CARBOXYARL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | BAYER HEALTHCARE LLC (US) | 2014-11-06 | — | — | US | disclosed |
| US-20140329866-A1 | OMEGA-CARBOXYARL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | BAYER HEALTHCARE LLC (US) | 2014-11-06 | — | — | US | disclosed |
| US-20140329866-A1 | OMEGA-CARBOXYARL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | BAYER HEALTHCARE LLC (US) | 2014-11-06 | — | — | US | disclosed |
| US-8841330-B2 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC (US) | 2014-09-23 | — | — | US | disclosed |
| US-8841330-B2 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC (US) | 2014-09-23 | — | — | US | disclosed |
| US-8841330-B2 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC (US) | 2014-09-23 | — | — | US | disclosed |
| US-20010034447-A1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC | 2001-10-25 | — | — | US | disclosed |
| EP-1140840-A1 | -G(V)-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | Bayer Corporation (US) | 2001-10-10 | — | — | EP | disclosed |
| US-20010027202-A1 | Omega-carboxyaryl substituted disphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC | 2001-10-04 | — | — | US | disclosed |
| US-20010016659-A1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC | 2001-08-23 | — | — | US | disclosed |
| US-20010011135-A1 | Omega-carboxyaryl subsituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC | 2001-08-02 | — | — | US | disclosed |
| US-20010011136-A1 | omega-carboxyyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC | 2001-08-02 | — | — | US | disclosed |
| EP-1111442-A1 | TREATING AGENT FOR LIQUID CRYSTAL ALIGNMENT LAYER AND LIQUID CRYSTAL DEVICE USING THE SAME, AND METHOD FOR ALIGNMENT OF LIQUID CRYSTAL | Nissan Chemical Industries, Ltd. (JP) | 2001-06-27 | — | — | EP | disclosed |
| WO-2000041698-A1 | φ-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS | BAYER CORPORATION (US) | 2000-07-20 | — | — | WO | disclosed |
| WO-2000042012-A1 | φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | BAYER CORPORATION (US) | 2000-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010011135-A1 | Omega-carboxyaryl subsituted diphenyl ureas as raf kinase inhibitors | BRAF, RAF1, ARAF | AKR1C3 1174/4885KMO 2324/4885ALDH1A1 1431/4885 |
| US-20010011136-A1 | omega-carboxyyaryl substituted diphenyl ureas as raf kinase inhibitors | BRAF, ARAF, RAF1 | AKR1C3 1500/4885KMO 2341/4885ALDH1A1 1887/4885 |
| US-20010034447-A1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BRAF, RAF1, ARAF | AKR1C3 1257/4885KMO 2133/4885ALDH1A1 1392/4885 |
| US-20010016659-A1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BRAF, RAF1, ARAF | AKR1C3 1257/4885KMO 2133/4885ALDH1A1 1392/4885 |
| US-20140329866-A1 | OMEGA-CARBOXYARL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | AKR1C3 852/4885KMO 2818/4885ALDH1A1 1800/4885 |
| US-20010027202-A1 | Omega-carboxyaryl substituted disphenyl ureas as raf kinase inhibitors | BRAF, NRAS, ARAF | AKR1C3 1603/4885KMO 2528/4885ALDH1A1 1474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.